Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when QTRX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsQuanterix names Anthony Catalano COO, restructures operations leadership
Filed May 26, 2026 · Period ending May 14, 2026 · ~1 min read
Key Changes
-
medium
Anthony Catalano appointed Chief Operating Officer effective May 14, 2026, with $400K base salary, 50% bonus target ($200K), and $50K sign-on bonus. He previously worked at Flagship Pioneering and joined Quanterix through the Akoya Biosciences acquisition.
Item 5.02 verify on EDGAR → -
medium
New COO received equity grant of 0.30% of outstanding shares via RSUs vesting over four years in equal annual installments, representing meaningful dilution but aligning executive interests with shareholders long-term.
Item 5.02 verify on EDGAR → -
medium
Former COO Michael Miller transitioned to Chief Technology and Products Officer rather than departing, indicating strategic restructuring to separate operational and technology leadership functions.
Item 5.02 verify on EDGAR → -
low
Catalano's severance package includes six months base salary plus pro-rated bonus for termination without cause; extends to nine months with full equity vesting acceleration in change-of-control scenarios.
Item 5.02 verify on EDGAR →
Summary
Quanterix executed a management restructuring by appointing Anthony Catalano as Chief Operating Officer while moving former COO Michael Miller into a newly created Chief Technology and Products Officer role. This split suggests the company is separating operational execution from technology development, potentially to sharpen focus on both commercial operations and product innovation.
Catalano brings relevant experience from the Akoya Biosciences integration and Flagship Pioneering. The compensation package is competitive for a mid-cap biotech COO, with total cash compensation around $600K annually and a 0.30% equity stake vesting over four years. The equity grant provides meaningful alignment but also represents dilution for existing shareholders.
Miller's retention in a senior technology role indicates this is a strategic reorganization rather than a performance-driven change. Investors should watch for operational improvements under the new structure, particularly in manufacturing efficiency and commercial execution. The next earnings call should provide clarity on how this leadership split will drive the business forward and whether the company sees technology development as a distinct strategic priority requiring dedicated C-suite attention.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Quanterix appointed Anthony Catalano as COO with $400K base salary, 50% bonus target, and 0.30% equity grant; former COO Michael Miller moved to CTO role.
Added in current filing · verify on EDGAR →
On May 14, 2026, Anthony Catalano was appointed as the Chief Operating Officer of Quanterix Corporation (the “Company”).
Anthony Catalano was appointed Chief Operating Officer effective May 14, 2026. He previously worked at Flagship Pioneering and had prior experience with the Company following its acquisition of Akoya Biosciences, where he served as SVP of Operations.
Added in current filing · verify on EDGAR →
Michael Miller, formerly the Chief Operating Officer of the Company, has transitioned to a new role as the Chief Technology and Products Officer of the Company.
The previous COO, Michael Miller, moved to a new role as Chief Technology and Products Officer rather than departing the company. This represents a management restructuring with the former COO remaining in an executive capacity focused on technology and products.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
If Mr. Catalano’s employment is terminated by the Company without Cause (as defined in the Employment Agreement) or he resigns for Good Reason (as defined in the Employment Agreement), then he will receive continued payment of his base salary for six months (the “Severance Period”), payment of an amount equal to his annual target bonus for the year of termination, pro-rated as of the date of termination, and subsidized health benefits during the Severance Period. If Mr. Catalano’s employment is terminated by the Company without Cause or he resigns for Good Reason in connection with a Change-in-Control (as defined in the Employment Agreement), then the Severance Period will be extended to nine months and all of his outstanding but unvested equity awards subject to time-based vesting will also become fully vested.
The COO employment agreement includes standard severance protections: six months base salary plus pro-rated bonus for termination without cause or resignation for good reason. In a change-of-control scenario, severance extends to nine months and all unvested time-based equity fully vests, providing downside protection.
Event · Item 9.01 — Financial Statements and Exhibits
Quanterix filed an employment agreement dated April 30, 2026 with Anthony Catalano.
Added in current filing · verify on EDGAR →
Employment Agreement dated April 30, 2026 between Anthony Catalano and the Company.
Quanterix entered into an employment agreement with Anthony Catalano effective April 30, 2026.The full agreement is attached as Exhibit 10.1.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 27, 2026 · How we verify